[The synthesis and carcinostatic effect of 4-[bis-(2-chloroethyl)-amino]-2, 3-dimethyl-1-phenyl-5-pyrazolone ("imet 3995")].
D000675:Ampyrone / Q000031:analogs & derivatives; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use / Q000633:toxicity; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000627:therapeutic use / Q000633:toxicity; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D004353:Drug Evaluation, Preclinical; D005260:Female; D007928:Lethal Dose 50; D007942:Leukemia, Experimental / Q000188:drug therapy; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D051379:Mice; D009588:Nitrogen Mustard Compounds / Q000138:chemical synthesis* / Q000627:therapeutic use / Q000633:toxicity; D051381:Rats; D012510:Sarcoma 180 / Q000188:drug therapy
D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D000675:Ampyrone; C010825:IMET 3995; D008558:Melphalan; D000983:Antipyrine
Synthese und cancerostatische Wirkung von 4-[Bis-(2-chloräthyl)-amino]-2,3-dimethyl-1-phenylpyrazolon-(5) ("IMET 3995")